We plan to invest Rs. 1,000 Cr in the next 3 to 4 years : Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Deal for 100 million doses with additional 100 million through 2023
AstraZeneca, Sinopharm and Moderna were part of the study
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
Aditya Puri former MD of HDFC bank joins Solara board as chairman
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Price band in the range of Rs 933 to Rs 954
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The first six batches are being shipped to the Gamaleya Center, Moscow for the quality approval
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
Subscribe To Our Newsletter & Stay Updated